Benzinga | Jan 31, 2022 04:51PM EST

Amgen Reports In 8K Filing Co Entered Into Amendment No. 3 To Exclusive License & Collaboration Agreement With Novartis

On January 31, 2022, the Company entered into Amendment No. 3 (the "Amendment") to the Exclusive License and Collaboration Agreement, dated August 28, 2015, as amended on April 21, 2017, by and between the Parties.

Pursuant to the Amendment (and as a result of the termination of the Amended and Restated Collaboration Agreement, dated June 2, 2021 (the "U.S. Collaboration Agreement"), by and between the Parties, described under Item 1.02 hereof), Novartis will hold sole rights to commercialize Aimovig outside of the United States and Japan, Amgen will no longer pay royalties to Novartis on sales of Aimovig in the United States, and the Parties will no longer share the costs of commercialization of Aimovig in the United States. The Parties will continue to share development expenses worldwide.

The foregoing description of the Amendment and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.